Showing results (271-280 of 305) with videos related to

Sort By:
Pageof 31
Cancer|January 8, 2015
A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinomaMairéad G McNamara, Lisa W Le, Anne M Horgan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 21, 2015
Prognostic factors for progression-free and overall survival in advanced biliary tract cancerJ Bridgewater, A Lopes, H Wasan, et al.
Acta Oncologica (Stockholm, Sweden)|April 8, 2022
Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapyKonstantinos Kamposioras, George Papaxoinis, Mohamed Dawood, et al.
British Journal of Cancer|July 22, 2022
Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancerMark K Doherty, Vincent C Tam, Mairéad G McNamara, et al.
American Journal of Clinical Oncology|February 28, 2014
Outcome of adjuvant therapy in biliary tract cancersMairead G McNamara, Thomas Walter, Anne M Horgan, et al.
Journal of Neuroendocrinology|February 14, 2022
Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module)John K Ramage, Elizabeth Friend, Jordan Randell, et al.
Journal of Neuroendocrinology|June 24, 2026
Characteristics, management, and outcomes of patients with VIPoma-A retrospective analysis of the ENETS databaseDetlef K Bartsch, L Mais, L de Mestier, et al.
World Journal of Gastroenterology|October 30, 2019
Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centresMelissa Frizziero, Xin Wang, Bipasha Chakrabarty, et al.
BMJ Open|February 8, 2020
NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)Zoe Craig, Jayne Swain, Emma Batman, et al.
BMJ Open|October 26, 2022
What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)? - a retrospective review of the published literatureMairéad G McNamara, John Bridgewater, Lipika Goyal, et al.
Pageof 31